3054-93-1

Upstream product

• 21955-58-8 (3-(2-methyl-1,3-dioxolan-2-yl)propyl)triphenylphosphonium iodide 
• 5944-33-2 (5-Brom-pentanon-(2)-aethylenacetal)-phosphoniumbromid 
• 5891-21-4 5-chloro-2-pentanone 
• 3695-28-1 5-iodo-2-pentanone ethylene ketal 
• 24400-75-7 ethylene-cetal de la bromo-5 pentanone-2 
• 603-35-0 triphenylphosphine 
• 539-88-8 4-oxopentanoic acid ethyl ester 
• 29021-98-5 3-(2-methyl-[1,3]dioxolan-2-yl)-propan-1-ol 
• 941-43-5 Ethyl levulinate ethylene ketal 
• 3695-29-2 5-iodo-2-pentanone 

Relevant academic research and scientific papers

GGA DERIVATIVES

This invention relates to geranylgeranyl acetone (GGA) derivatives, pharmaceutical compositions comprising GGA derivatives and the use of GGA derivatives.

METHODS FOR TREATING NEURON DAMAGE

This invention relates to the use of geranylgeranyl acetone (GGA), its isomers, and GGA derivatives in a method for for treating a disease in a subject mediated in part by miRNA-378 or miRNA-711 increased activity comprising administering to the subject a therapeutically effective amount of 5-trans-GGA or a derivative thereof.

GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM

This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

GGA AND GGA DERIVATIVES, COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM

This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

METHODS FOR TREATING NEURODEGENERATIVE DISEASES

This invention relates to the 5-cis and 5-trans isomers of geranylgeranyl acetone, preferably such synthetic isomers, and pharmaceutical compositions containing such isomers. Other aspects of this invention relate to the use of geranylgeranyl acetone and its isomers in methods for inhibiting neural death, increasing neural activity, and increasing axon growth and cell viability. Geranylgeranyl acetone is a known anti-ulcer drug used commercially and in clinical situations. GGA has also been shown to exert cytoprotective effects on a variety of organs, such as the eye, brain, and heart.

The Cyclisation of Geraniol in Superacids

The cyclisation of geraniol (1) in FSO3H-SO2 at -78 deg C to yield the iridoid ether 3β,4α,6aα-trimethyl-cis-perhydrocyclopentafuran was investigated.Decomposition of the ether in FSO3H at room temperature gave the 2-isopropyl-1,3-dimethylcyclopentenium ion, whose structure was confirmed independently.Synthesis of geraniol labelled with deuterium on the gem-dimethyl group and on the single methyl group established the positions of these mehtyls in the iridoid ether.Synthesis of 2-(1-hydroxy-2,2-dimethylcyclopentyl)propan-1-ol established that the ion derived from it did not lie on the reaction pathway.

SYNTHESIS OF (+)-TRICYCLOHEXAPRENOL, A POSSIBLE PRECURSOR OF A FAMILY OF TRICYCLIC GEOTERPANES, AND SYNTHESIS OF AN ISOMER.

A synthesis of (+)-tricyclohexaprenol 2 starting from isocopalenol 8 and a synthesis of its isomer 4 starting from ent-(14αH)-isocopalenol 26 are described.